TPC Safety Study Published in JCO Precision Oncology

Multi-Omics Guidance Safe for Advanced Melanoma Treatment

The Tumor Profiler Consortium celebrates the publication of a comprehensive safety analysis demonstrating that multi-omics-guided therapy selection is safe and feasible for patients with advanced melanoma. The study, published in JCO Precision Oncology, represents the first comparative safety analysis of multi-omics informed therapies.

The study compared 98 TuPro melanoma patients who received multi-omics-guided treatment selection with a matched retrospective cohort. Key findings showed that personalised treatment enabled significantly more beyond standard-of-care therapies without increasing high-grade adverse events, hospitalisation rates, or treatment-related costs.

Multi-omics-guided therapy selection allowed for more treatments beyond standard of care without increasing rates of high-grade adverse events, hospitalisations, or adverse event-related costs. Low-grade adverse events were more frequent and occurred earlier but were shorter in duration and showed higher recovery rates.

First author Benedict Gosztonyi and senior authors Prof. Dr. Andreas Wicki, Prof. Dr. Mitchell Levesque, and Prof. Dr. Reinhard Dummer led this important work alongside the broader Tumor Profiler Consortium. The findings support the clinical feasibility and safety of multi-omics-guided therapies, demonstrating their potential to expand treatment opportunities whilst maintaining manageable safety risks.

Publication: Gosztonyi B, Mehra T, Gut G, et al. Safety of Multi-Omics–Guided Therapy in Advanced Melanoma: A Matched Comparative Cohort Analysis. JCO Precision Oncology 2026;10:e2500896. DOI: 10.1200/PO-25-00896

Published online: 25 February 2026